Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

$29.47

-0.38 (-1.27%)

(As of 09/27/2024 ET)

Apellis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
0

Hold
4

Buy
11

Based on 15 Wall Street analysts who have issued ratings for Apellis Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 4 have given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for APLS.

Consensus Price Target

$70.20
138.21% Upside

According to the 15 analysts' twelve-month price targets for Apellis Pharmaceuticals, the average price target is $70.20. The highest price target for APLS is $106.00, while the lowest price target for APLS is $39.00. The average price target represents a forecasted upside of 138.21% from the current price of $29.47.

Get the Latest News and Ratings for APLS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Apellis Pharmaceuticals and its competitors.

APLS Analyst Ratings Over Time

Type	Current Forecast 9/30/23 to 9/29/24	1 Month Ago 8/31/23 to 8/30/24	3 Months Ago 7/2/23 to 7/1/24	1 Year Ago 9/30/22 to 9/30/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	10 Buy rating(s)	10 Buy rating(s)	11 Buy rating(s)	9 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$70.20	$72.13	$75.56	$66.13
Forecasted Upside	138.21% Upside	85.43% Upside	108.22% Upside	73.85% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

NOTICE: You have until Tuesday, November 19th (Ad)

On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...

Click here for the ticker >>>

APLS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

APLS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Apellis Pharmaceuticals Stock vs. The Competition

Type	Apellis Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	138.21% Upside	818.50% Upside	6.16% Upside
News Sentiment Rating	Neutral News See Recent APLS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/24/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Equal Weight ➝ Equal Weight	$47.00 ➝ $43.00	+36.42%
9/23/2024	Robert W. Baird 2 of 5 stars		Lower Target	Outperform ➝ Outperform	$96.00 ➝ $92.00	+182.99%
9/20/2024	Mizuho 2 of 5 stars		Lower Target	Neutral ➝ Neutral	$42.00 ➝ $39.00	+25.12%
9/20/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$85.00 ➝ $85.00	+166.96%
9/13/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$64.00 ➝ $57.00	+52.00%
8/9/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$85.00 ➝ $83.00	+119.34%
Get the Latest News and Ratings for APLS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
8/9/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$38.00 ➝ $41.00	+8.72%
8/9/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$66.00 ➝ $74.00	+96.49%
8/2/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$92.00 ➝ $83.00	+127.02%
7/31/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00	+100.20%
5/31/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Amin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$46.00	+12.88%
5/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$67.00 ➝ $60.00	+41.84%
1/30/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$75.00 ➝ $79.00	+20.78%
1/11/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Strong-Buy ➝ Strong-Buy	$67.00 ➝ $106.00	+60.85%
12/5/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$52.00 ➝ $85.00	+33.08%
8/29/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$60.00 ➝ $65.00	+63.73%
11/8/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$45.00 ➝ $43.00	-9.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:37 PM ET.

APLS Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Apellis Pharmaceuticals is $70.20, with a high forecast of $106.00 and a low forecast of $39.00.
: 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 4 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" APLS shares.
: According to analysts, Apellis Pharmaceuticals's stock has a predicted upside of 138.21% based on their 12-month stock forecasts.
: Apellis Pharmaceuticals has been rated by research analysts at HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Mizuho, Needham & Company LLC, Robert W. Baird, The Goldman Sachs Group, UBS Group, Wedbush, and Wells Fargo & Company in the past 90 days.
: Analysts like Apellis Pharmaceuticals more than other "medical" companies. The consensus rating score for Apellis Pharmaceuticals is 2.80 while the average consensus rating score for "medical" companies is 2.78. Learn more on how APLS compares to other companies.